Replies to post #2218 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

The main difference between the latest slide set and the previous version is on slide #15, which shows in vitro assays for EDP-323, the L-protein inhibitor for RSV.

[DewDiligence]

ENTA’s phase-2b trial in RSV misses primary endpoint:

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-topline-data-rsvp-study-edp-938

From the recent price action, it seems that this result may have been leaked.

[DewDiligence]

New corporate slide set (5/18/22):

https://ir.enanta.com/static-files/fb5db89a-b15b-4820-9e77-b8c5b087f869

Only update is the RSVP result.